Back to Urology
UrologyvModified_2014Evidence-Based

Gleason Score for Prostate Cancer

Histologic grading system for prostate cancer based on microscopic tumor architecture patterns. Uses primary and secondary tumor patterns to predict prognosis and guide treatment decisions. The score combines the two most prevalent architectural patterns found in the tumor specimen.

Clinical Input Parameters

grade
grade
Clinical Assessment
Awaiting Parameters
gleason score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Gleason Score for Prostate Cancer is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within urology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Gleason Score = Primary Grade + Secondary Grade (range 6-10). Grade Groups: GG1=6, GG2=3+4=7, GG3=4+3=7, GG4=8, GG5=9-10

Clinical Pearls & Practice Notes

  • Currently, the lowest Gleason grade assigned is 3 (grades 1-2 represent normal/benign tissue)
  • Primary grade must represent >50% of tumor, secondary grade ≥5% but <50%
  • Score of 3+4=7 (Grade Group 2) has better prognosis than 4+3=7 (Grade Group 3)
  • Gleason 6 tumors are considered low-grade and may be managed with active surveillance
  • Grade Groups (1-5) are increasingly used instead of traditional Gleason scores
  • Higher scores correlate with increased risk of metastasis and cancer-specific mortality
  • Used in conjunction with PSA levels and clinical stage for risk stratification
  • Modern ISUP 2014 guidelines have refined grading criteria for greater consistency
  • Tertiary patterns (if >5% of tumor) may influence prognosis but don't change score
  • Inter-observer variability exists; expert genitourinary pathology review recommended
  • Needle biopsy grades may differ from final prostatectomy specimen grades
  • Score influences treatment selection: surgery, radiation, hormone therapy, surveillance
  • Essential component of D'Amico risk classification system
  • Prognostic value maintained across different treatment modalities and patient populations

Evidence & Literature Citations

  1. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58-64.
  2. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40(2):244-252. doi: 10.1097/PAS.0000000000000530.
  3. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111(5):753-760. doi: 10.1111/j.1464-410X.2012.11611.x.
  4. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974. doi: 10.1001/jama.280.11.969.

Score Interpretation Ranges

Low-Grade Cancer (Grade Group 1)6 – 6 pts

Well-differentiated, favorable prognosis

Intermediate-Grade Cancer (Grade Group 2-3)7 – 7 pts

Moderately differentiated, intermediate prognosis

High-Grade Cancer (Grade Group 4)8 – 8 pts

Poorly differentiated, unfavorable prognosis

Very High-Grade Cancer (Grade Group 5)9 – 10 pts

Very poorly differentiated, very unfavorable prognosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.